CD274 and non-small cell lung carcinoma: Taking into consideration those weaknesses as described, our study gives an overview of the therapeutic strategies for patients with advanced NSCLC and PD-L1 ≥ 50% proposed in diverse types of French medical institutions (University hospitals, Cancer Centres, Public and Private hospitals).